What are the odds of developing ovarian cancer?
Evidence quality 4.5/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 4/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 91
1.1% lifetime chance
Most people overestimate this.
range 1 in 125 to 1 in 77
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Ovarian cancer occupies a disproportionate space in the public fear landscape relative to its actual incidence — partly because it is often diagnosed late, partly because the early-detection story is far less reassuring than for breast or cervical cancer. There is no reliable population-level screening test, and the "silent killer" framing in media coverage reinforces the sense that the disease strikes without warning. Most women cannot distinguish between the lifetime risk of ovarian cancer (~1%) and the lifetime risk of breast cancer (~13%), and the two are frequently conflated in casual conversation about "women's cancers."
Rough estimate: Many adults assume ovarian cancer is nearly as common as breast cancer
Source: editorial intuition, not polled
Actual
~1 in 91 US women lifetime risk of diagnosis
US women, all ages
Show derivation
The American Cancer Society estimates a US woman's lifetime risk of developing ovarian cancer at approximately 1 in 91 (~1.1%), based on SEER incidence data. SEER confirms approximately 1.1% of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2021-2023 data. The ACS projects ~21,010 new cases and ~12,450 deaths in 2026. Lifetime risk of dying from ovarian cancer is lower, about 1 in 143 (~0.7%), because roughly 50% of cases are now survived. Point estimate 0.011 for incidence; uncertainty band reflects the range between the death-only figure (~0.007) and older, higher historical incidence estimates (~0.013) before the secular decline driven by oral contraceptive use and reduced hormone therapy.
Caveats: This entry is lifetime *incidence* (diagnosis), not mortality. Ovarian cancer's …
This entry is lifetime *incidence* (diagnosis), not mortality. Ovarian cancer's case-fatality rate is high compared to other gynecological cancers — roughly 60% of women diagnosed will eventually die of the disease — because no effective population screening test exists and most cases are diagnosed at advanced stage. The "silent killer" label is partly earned: early-stage symptoms are nonspecific and easily attributed to other causes. However, the baseline lifetime risk of developing ovarian cancer (~1 in 91) is roughly 12x lower than the equivalent figure for breast cancer (~1 in 8), a gap many people do not appreciate.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| US women (all races) | 1 in 91 |
ACS/SEER: ~1 in 91 lifetime incidence |
| US White women | 1 in 83 |
Slightly higher age-adjusted incidence than Black women |
| US Black women | 1 in 111 |
Lower incidence but higher case-fatality and later-stage diagnosis on average |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The American Cancer Society puts a US woman’s lifetime risk of developing ovarian cancer at about 1 in 91 (~1.1%), based on SEER registry data. That makes it roughly twelve times rarer than breast cancer at diagnosis — a gap most people do not appreciate, because media coverage of “women’s cancers” tends to blur the boundaries between very different diseases. The ACS projects about 21,010 new cases and 12,450 deaths in 2026, and SEER’s five-year relative survival sits at roughly 51%, far below the 92% figure for breast cancer. The difference is almost entirely about stage at detection: there is no PAP-smear equivalent for the ovaries, and most ovarian cancers are caught after they have spread beyond the pelvis.
The “silent killer” label is partly earned and partly misleading. Early-stage ovarian cancer does produce symptoms — bloating, pelvic pain, urinary urgency, early satiety — but those symptoms are nonspecific and overlap heavily with common gastrointestinal and urinary complaints. The consequence is diagnostic delay, not genuine silence. Ovarian cancer incidence has actually declined over the past several decades, driven primarily by wider use of oral contraceptives (which reduce risk by roughly 50% with five or more years of use) and reduced prescribing of menopausal hormone therapy. The rate of ovarian cancer deaths has fallen by about 45% since 1976, with most of that progress concentrated after the mid-2000s.
The sharpest personal risk modifier is genetic. Carriers of a pathogenic BRCA1 variant face a lifetime ovarian cancer risk of roughly 39-44%, compared to the ~1.1% baseline — a multiplier of about 35x. BRCA2 carriers run a lifetime risk of roughly 11-17%. These figures are clinically important but affect a small fraction of the population (roughly 1 in 400-500 women carry a BRCA1/2 pathogenic variant). First-degree family history of ovarian cancer roughly triples baseline risk even without a known gene variant. For the vast majority of women without known genetic risk factors, ovarian cancer remains an uncommon disease with a serious prognosis — the kind of risk that warrants awareness without warranting alarm.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] American Cancer Society — Key Statistics for Ovarian Cancer
Key Statistics for Ovarian Cancer- Statistic
Lifetime risk ~1 in 91; ~21,010 new cases and ~12,450 deaths projected for 2026- Excerpt
“"A woman's risk of getting ovarian cancer during her lifetime is about 1 in 91. Her lifetime chance of dying from ovarian cancer is about 1 in 143. [...] The American Cancer Society estimates that in 2026, about 21,010 new cases of ovarian cancer will be diagnosed and 12,450 women will die of ovarian cancer in the United States." ”
- Source data from
- 2026-01-13
- Accessed
- 2026-04-24 · archived copy
- Calculation
- ACS gives lifetime incidence directly as ~1 in 91 (~1.1%) and lifetime mortality as ~1 in 143 (~0.7%). The headline figure used here is incidence, not mortality, because the question asks about developing ovarian cancer, not dying from it. The ~60% case-fatality implied by the ratio (0.7/1.1) is considerably higher than for breast cancer (~18%), reflecting later-stage diagnosis on average and the absence of an effective screening test.
- Independence
- ACS derives its lifetime-probability figures from SEER incidence and mortality data (NCI). Treat as partially dependent with the SEER source below.
-
[2] National Cancer Institute / SEER Program — Cancer Stat Facts: Ovarian Cancer
Cancer Stat Facts: Ovarian Cancer- Statistic
Approximately 1.1% of women will be diagnosed with ovarian cancer at some point during their lifetime- Excerpt
“"Approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2021–2023 data." ”
- Source data from
- 2025-04-17
- Accessed
- 2026-04-24 · archived copy
- Calculation
- SEER provides the upstream population-registry data from which ACS derives its headline figures. The 1.1% lifetime risk is consistent with the ACS "1 in 91" figure. Five-year relative survival for ovarian cancer is approximately 51%, far lower than for breast cancer (91.7%), which is why the diagnosis-to-death gap is narrower here.
- Independence
- SEER is the upstream data source that ACS cites; treat these two as partially dependent. SEER is included as the authoritative primary-pipeline citation.